Prone Positioning in Pediatric Acute Lung Injury

NCT ID: NCT00133614

Last Updated: 2005-10-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

102 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-08-31

Study Completion Date

2004-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to test the hypothesis that at the end of 28 days, infants and children with acute lung injury treated with prone positioning would have more ventilator-free days than those treated with supine positioning.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multicenter, randomized, controlled clinical trial conducted from August 28, 2001 to April 23, 2004, of 102 pediatric patients from 7 US pediatric intensive care units aged 2 weeks to 18 years who were treated with supine vs. prone positioning. Randomization was concealed and group assignment was not blinded.

Patients were randomized to either supine or prone positioning within 48 hours of meeting acute lung injury criteria, with those patients in the prone group being positioned within 4 hours of randomization and remaining prone for 20 hours each day during the acute phase of their illness for a maximum of 7 days, after which they were positioned supine. Both groups were treated using lung protective ventilator and sedation protocols, extubation readiness testing, and hemodynamic, nutrition, and skin care guidelines.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Lung Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prone Positioning

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>42 weeks post-conceptual age and \<18 years of age
* On mechanical ventilation (defined as presence of an endotracheal/tracheostomy tube and currently using ventilator support)
* All of the following in the same 48 hour period:

* acute pulmonary parenchymal disease (i.e., chest radiograph report of diffuse bilateral pulmonary alveolar infiltrates)
* mechanical ventilation for at least 1 hour and anticipated need to continue mechanical ventilation for at least 24 hours
* at least one PaO2/FiO2 ratio \<300 (adjusted for barometric pressure: if altitude \> 1000m, then PaO2/FiO2 \<= 300x(B.P./760), regardless of mean airway pressure)
* functional arterial catheter for blood gas analysis

Exclusion Criteria

* Persistent hypotension (defined as systolic blood pressure of 70mmHg+(2x age in years)); i.e. patients requiring either intravenous fluids and/or increases of additional cardiotonic medications every 2 hours
* Active bleeding that requires ongoing blood/fluid volume replacement
* Currently on extracorporeal membrane oxygenation (ECMO)
* Severe chronic lung disease (cystic fibrosis or bronchopulmonary dysplasia)
* Respiratory failure presumed to be the result of cardiac disease
* History of symptomatic or uncorrected congenital heart disease or a right to left intracardiac shunt
* Bone marrow or lung transplant
* Current known diagnosis of any of the following:

* upper airway disease (i.e., tracheitis, tracheomalacia)
* reactive airway disease (receiving beta agonists or acute doses of systemic corticosteroids)
* refractory cerebral hypertension (intracranial pressure \[ICP\] \>20mmHg for 1 hr)
* neuromuscular respiratory failure (chronic assisted ventilation)
* spinal instability (uncleared cervical spine)
* unstable long bone fractures
* Nonpulmonary condition that may be exacerbated by the prone position (for example, osteogenesis imperfecta, craniofacial surgery in the past week)
* Draining abdominal surgical wound
* Pregnancy
* Subject's family/medical team have decided not to provide full support (patient treatment considered futile)
* Enrollment in any other clinical trial within the last 30 days
Minimum Eligible Age

2 Weeks

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institutes of Health (NIH)

NIH

Sponsor Role collaborator

National Institute of Nursing Research (NINR)

NIH

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martha Curley, RN,PhD,FAAN

Role: PRINCIPAL_INVESTIGATOR

Boston Children's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Childrens Hospital, Boston

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Curley MA, Hibberd PL, Fineman LD, Wypij D, Shih MC, Thompson JE, Grant MJ, Barr FE, Cvijanovich NZ, Sorce L, Luckett PM, Matthay MA, Arnold JH. Effect of prone positioning on clinical outcomes in children with acute lung injury: a randomized controlled trial. JAMA. 2005 Jul 13;294(2):229-37. doi: 10.1001/jama.294.2.229.

Reference Type RESULT
PMID: 16014597 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

5R01NR005336-04

Identifier Type: NIH

Identifier Source: secondary_id

View Link

5336

Identifier Type: -

Identifier Source: org_study_id